Bayer in licenses Puhe BioPharma’s cancer candidate

Eoneren German conglomerate Bayer ( OTCPK:BAYZF ) announced Wednesday a global license agreement with Puhe BioPharma to co-develop the Chinese biotech’s experimental therapy designed to target a cancer type known as MTAP-deleted tumors. Per the deal terms, Bayer ( OTCPK:BAYRY ) will receive an.